Local Stage Dependent Necessity of Radiation Therapy in Rhabdoid Tumors of the Kidney (RTK).


Journal

International journal of radiation oncology, biology, physics
ISSN: 1879-355X
Titre abrégé: Int J Radiat Oncol Biol Phys
Pays: United States
ID NLM: 7603616

Informations de publication

Date de publication:
01 11 2020
Historique:
received: 17 12 2019
revised: 15 03 2020
accepted: 30 04 2020
pubmed: 15 5 2020
medline: 10 4 2021
entrez: 15 5 2020
Statut: ppublish

Résumé

Rhabdoid tumor of the kidney (RTK) is one of the most aggressive childhood renal tumors. Overall survival ranges from 22% to 47%. The indication for radiation therapy (RT) in usually very young patients is an ongoing discussion. Recent protocols recommend RT independent of local stage, the latter being a good discriminator in other childhood kidney tumors. In this study, we analyze the evidence for RT in regard to risk factors, including tumor stage. This study analyzed 58 patients with RTK from Austria, Switzerland, and Germany treated in the framework of 4 consecutive, prospective renal/rhabdoid tumor studies from 1991 to 2014. All treatment protocols included multimodality treatment, including high-intensity chemotherapy, surgery, and RT. Local stage distribution was not applicable, I, II, and III in 1, 6, 11, and 40, respectively. Twenty-nine (50%) patients had stage IV disease at diagnosis. Thirty-seven patients (64%) achieved complete remission, and 49% (18/37) relapsed. Thirty-four patients (60%) patients had progressive disease and died, 17 had local disease, 10 had combined disease, and 7 had distant disease; 2 treatment-related deaths were reported (3%). Twenty-one patients received RT during first-line treatment, 18 of them to all involved sites. Eight of the 34 cases of progressive disease occurred in irradiated patients. The local failure rate of treated patients with local stage II or III disease was 29% (6/18) in patients irradiated to all sites compared with 68% (15/22) in nonirradiated patients. One of 6 stage I patients received RT, and 1 patient experienced distant relapse (2-year progression-free and overall survival both 83% ± 15%). Progression-free survival for local stage II and III disease treated with RT, adjusted for early relapse or treatment abandonment, was 67% ± 11%, compared with 15% ± 7% without RT (P < .0001). The 68% local failure rate in nonirradiated patients underlines the importance of local treatment. Our experience supports the use of RT for local control in higher stage disease. In contrast, no local relapse in 6 local stage I patients, including 5 nonirradiated patients, suggests omission of RT in this favorable subset of usually infant patients with RTK.

Identifiants

pubmed: 32407933
pii: S0360-3016(20)31123-8
doi: 10.1016/j.ijrobp.2020.04.046
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

667-675

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Auteurs

Patrick Melchior (P)

Department of Radiation Oncology, Saarland University Hospital, Homburg, Germany. Electronic address: patrick.melchior@uks.eu.

Yvonne Dzierma (Y)

Department of Radiation Oncology, Saarland University Hospital, Homburg, Germany.

Christian Rübe (C)

Department of Radiation Oncology, Saarland University Hospital, Homburg, Germany.

Norbert Graf (N)

Department of Pediatric Hematology and Oncology, Saarland University Hospital, Homburg/Saar, Germany.

Leo Kager (L)

St. Anna Children's Hospital, Department of Pediatrics, Medical University Vienna, Vienna, Austria.

Karin Dieckmann (K)

Department of Radiation Oncology, Medical University Vienna, Vienna, Austria.

Sabine Kroiss (S)

Department of Pediatric Hematology and Oncology, Children's Hospital, Zurich University, Zurich, Switzerland.

Jochen Hubertus (J)

Department of Pediatric Surgery, von Haunersches Kinderspital, Ludwigs-Maximilians University, Munich, Germany.

Steven Warmann (S)

Department of Pediatric Surgery, Tübingen University Hospital, Tübingen, Germany.

Jens-Peter Schenk (JP)

Department of Radiology, Heidelberg University Hospital, Heidelberg, Germany.

Ivo Leuschner (I)

Department of Paidopathology, Schleswig-Holstein-University Hospital, Campus Kiel, Kiel, Germany; Section of Pediatric Pathology, Department of Pathology, University Hospital Bonn, Bonn, Germany.

Karolina Nemes (K)

Swabian Children's Cancer Center, University Children's Hospital Augsburg, Augsburg, Germany.

Clemens Magnus Meier (CM)

Section of Pediatric Surgery, Saarland University Hospital, Homburg, Germany.

Christian Vokuhl (C)

Department of Paidopathology, Schleswig-Holstein-University Hospital, Campus Kiel, Kiel, Germany; Deceased.

Michael Frühwald (M)

Swabian Children's Cancer Center, University Children's Hospital Augsburg, Augsburg, Germany.

Rhoikos Furtwängler (R)

Department of Pediatric Hematology and Oncology, Saarland University Hospital, Homburg/Saar, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH